Why patent disputes end in settlements, and what that does to launch dates

Most disputes end before the last judgment

Case reports give the impression that courts decide when a generic or biosimilar reaches the market. More often the parties do. In the first half of November 2026 two of Europe’s largest patent fights ended this way within a week. ZTE and Samsung withdrew their actions against each other at the Unified Patent Court (UPC) after two years of litigation over mobile phone patents in Europe, China and the Americas. GSK and Moderna announced the end of their dispute over the lipid technology in mRNA vaccines, in the US and in Europe, four days before the court in The Hague ruled on the same patent against Pfizer and BioNTech.

Medicines follow the same pattern. Of the biosimilars that reached Europe in the past two years, denosumab, ustekinumab, pertuzumab and most suppliers of aflibercept arrived on dates agreed in a licence, as the autumn 2026 watch list sets out. For denosumab there was no European court case at all.

For anyone planning around a loss of exclusivity this matters for one reason: the date in a settlement appears on no register. The patent stays in force. So does the supplementary protection certificate. The product launches anyway, earlier, under licence.

Why each side settles

The originator. A judgment that revokes a patent opens the market to every competitor at once. A licence to the one company that challenged it leaves the patent standing against all the others. Settling also replaces an uncertain date with a known one, which is easier to plan production, pricing and tenders around.

The challenger. A licensed date is certain and is usually earlier than expiry. It removes the risk of launching, being enjoined and paying damages. And the alternative is slow and expensive: clearing a patent through trial and appeal in the UK takes two to three years, as the explainer on clearing the path describes.

Both, once a court has spoken. Decisions set the terms. When the UK Patents Court held in October 2025 that aflibercept biosimilars did not infringe the formulation patent, every biosimilar maker that had not already launched took a licence within four months, with UK entry at once or from January 2026 and EU entry from April and May 2026. The aflibercept case note has the sequence.

Courts can also build the negotiation into the order. In GSK v Pfizer and BioNTech the UPC granted an injunction that cannot be enforced until the decision is final and three further months have passed without a licence. The judgment is, in effect, a deadline to agree.

The UPC raises the stakes on both sides. One decision covers eighteen countries, and since 2025 an order can reach countries outside the court’s territory as well. The more a single judgment can lose, the stronger the reason to agree before it is given.

What a settlement usually contains

The terms are confidential, so this is a description of what companies have chosen to disclose.

• A licensed entry date, often different by territory. UK, EU and US dates for the same product commonly differ, and European dates are sometimes agreed as part of a settlement of US litigation, as with denosumab.
• Withdrawal of the actions, usually with each side bearing its own costs. Oppositions at the European Patent Office may be withdrawn as part of the same deal.
• Money or patents in either direction. A royalty to the originator is common. Where both sides hold patents the other needs, a cross-licence may replace payment altogether: GSK and Moderna licensed each other in the field of infectious disease and neither pays anything.

A settlement with the first challenger also tends to set the date for the rest. Later challengers know a licence is available and on roughly what terms, and the originator has little reason to hold out against them.

The limit: paying a competitor to stay out

A settlement between a patent holder and a would-be competitor is an agreement between competitors, and EU competition law applies to it. The Court of Justice set the test in 2020 in Generics (UK) v CMA, a case about paroxetine: a settlement restricts competition by its very object where the originator transfers value to the generic and that transfer has no explanation other than the two companies’ shared interest in not competing. The Court applied the same reasoning to uphold fines on Lundbeck over citalopram in 2021 and on Teva and Cephalon over modafinil in October 2025.

The line is narrower than the phrase “pay-for-delay” suggests. A settlement that lets the generic in before expiry, with no payment flowing to the generic, is the ordinary and lawful kind. The same is true of payments with a genuine explanation, such as a contribution to litigation costs or a price for real goods or services. What is caught is the payment whose only purpose is to buy the challenger’s absence.

How a settlement shows up

Since the register will not show it, the signs are indirect.

• Withdrawal orders. At the UPC a claimant needs the court’s permission to withdraw, and the decision is published. Mutual withdrawals without any application for costs are the usual sign, as JUVE Patent noted of ZTE and Samsung. The court can also confirm a settlement by decision and order its details to be kept confidential.
• Company statements. Listed companies often announce a settlement, and the originator’s quarterly report may list the licensed dates. Moderna’s statement gave the date and the essentials of its agreement with GSK.
• An authorisation that sits unused. A biosimilar with a marketing authorisation, a price and no launch may be waiting for a licensed date.
• A withdrawn opposition. If the opponents leave an EPO opposition, the patent may stand as it is. A company that joined only at the appeal stage cannot keep the case alive alone, as the explainer on the Enlarged Board’s recent decisions explains.
• Several launches on one day. Six or more denosumab biosimilars reached EU markets on 1 and 2 December 2025. Dates that line up like that are agreed, not litigated.

What to do with this

A generics or biosimilar planner. The first settlement on a molecule is market information as much as legal news: it tells you a date is available and roughly when. If you intend to challenge, the patent office and the court are both routes to the table as well as to a judgment.

A parallel trader or wholesaler. The first sign of multi-source supply may be a press release, not a ruling or a change on a register. Licensed dates differ by territory, so a UK launch under licence says nothing certain about the EU date, and the reverse.

Anyone reading a register. The expiry date is the latest the market can open, not the date it will. Why the two differ, in both directions, is the subject of why the expiry date is not the launch date.